Trials / Completed
CompletedNCT00769496
BAY 77-1931 Long-term Extension From Phase II Study
A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY 77-1931 | Lanthanum Carbonate (BAY 77-1931) |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-10-09
- Last updated
- 2013-01-23
Locations
14 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00769496. Inclusion in this directory is not an endorsement.